Melatonin for treatment of sleep disorders in children with developmental disabilities

N. N. Dodge, G. A. Wilson

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

This study explored the safety and efficacy of synthetic melatonin in the treatment of sleep problems in 20 children with developmental disabilities, in a randomized, double-blind, placebo-controlled 6-week trial of melatonin versus placebo. All but 2 children fell asleep more quickly when receiving melatonin than placebo. Overall, the greater the sleep latency (time to fall asleep) was at baseline or when receiving placebo, the more pronounced was the decrease in sleep latency with melatonin. The effect of melatonin on sleep latency was significant (P <.05). The duration of sleep while receiving melatonin was significantly greater than baseline (P <.007) but was not significantly different from placebo, and no difference in the number of awakenings was noted. No side effects were reported. Eleven of 18 parents (61%) correctly identified the weeks their child received melatonin. This study suggests that synthetic melatonin reduces sleep latency in children with developmental disabilities.

Original languageEnglish (US)
Pages (from-to)581-584
Number of pages4
JournalJournal of Child Neurology
Volume16
Issue number8
StatePublished - 2001
Externally publishedYes

Fingerprint

Developmental Disabilities
Disabled Children
Melatonin
Sleep
Placebos
Therapeutics
Sleep Wake Disorders
Parents
Safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Melatonin for treatment of sleep disorders in children with developmental disabilities. / Dodge, N. N.; Wilson, G. A.

In: Journal of Child Neurology, Vol. 16, No. 8, 2001, p. 581-584.

Research output: Contribution to journalArticle

@article{db99f3256c8441b2a600ec256a627664,
title = "Melatonin for treatment of sleep disorders in children with developmental disabilities",
abstract = "This study explored the safety and efficacy of synthetic melatonin in the treatment of sleep problems in 20 children with developmental disabilities, in a randomized, double-blind, placebo-controlled 6-week trial of melatonin versus placebo. All but 2 children fell asleep more quickly when receiving melatonin than placebo. Overall, the greater the sleep latency (time to fall asleep) was at baseline or when receiving placebo, the more pronounced was the decrease in sleep latency with melatonin. The effect of melatonin on sleep latency was significant (P <.05). The duration of sleep while receiving melatonin was significantly greater than baseline (P <.007) but was not significantly different from placebo, and no difference in the number of awakenings was noted. No side effects were reported. Eleven of 18 parents (61{\%}) correctly identified the weeks their child received melatonin. This study suggests that synthetic melatonin reduces sleep latency in children with developmental disabilities.",
author = "Dodge, {N. N.} and Wilson, {G. A.}",
year = "2001",
language = "English (US)",
volume = "16",
pages = "581--584",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Melatonin for treatment of sleep disorders in children with developmental disabilities

AU - Dodge, N. N.

AU - Wilson, G. A.

PY - 2001

Y1 - 2001

N2 - This study explored the safety and efficacy of synthetic melatonin in the treatment of sleep problems in 20 children with developmental disabilities, in a randomized, double-blind, placebo-controlled 6-week trial of melatonin versus placebo. All but 2 children fell asleep more quickly when receiving melatonin than placebo. Overall, the greater the sleep latency (time to fall asleep) was at baseline or when receiving placebo, the more pronounced was the decrease in sleep latency with melatonin. The effect of melatonin on sleep latency was significant (P <.05). The duration of sleep while receiving melatonin was significantly greater than baseline (P <.007) but was not significantly different from placebo, and no difference in the number of awakenings was noted. No side effects were reported. Eleven of 18 parents (61%) correctly identified the weeks their child received melatonin. This study suggests that synthetic melatonin reduces sleep latency in children with developmental disabilities.

AB - This study explored the safety and efficacy of synthetic melatonin in the treatment of sleep problems in 20 children with developmental disabilities, in a randomized, double-blind, placebo-controlled 6-week trial of melatonin versus placebo. All but 2 children fell asleep more quickly when receiving melatonin than placebo. Overall, the greater the sleep latency (time to fall asleep) was at baseline or when receiving placebo, the more pronounced was the decrease in sleep latency with melatonin. The effect of melatonin on sleep latency was significant (P <.05). The duration of sleep while receiving melatonin was significantly greater than baseline (P <.007) but was not significantly different from placebo, and no difference in the number of awakenings was noted. No side effects were reported. Eleven of 18 parents (61%) correctly identified the weeks their child received melatonin. This study suggests that synthetic melatonin reduces sleep latency in children with developmental disabilities.

UR - http://www.scopus.com/inward/record.url?scp=0034857323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034857323&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 581

EP - 584

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 8

ER -